Study of the Association between PSA, Hormonal and Hematological Parameters in Prostate Cancer Patients in Southern Libya
DOI:
https://doi.org/10.61952/jlabw.v1i3.188Keywords:
Prostate cancer, PSA, Testosterone, Hormones, Urinary symptomsAbstract
With a focus on their impact on diagnostic markers like prostate-specific antigen (PSA), this study examined behavioural, hormonal, biochemical, and demographic aspects associated with prostate cancer. There were 54 male participants in all, ages 50 to 90, including 25 healthy controls and 29 patients with prostate cancer. Between July 2024 and February 2025, information was gathered from the Al-Firdous Clinic Laboratory in Brack Al-Shati and the Cancer Centre in Sebha. With a significance level of p < 0.05 and effect sizes determined using Cohen's classification, statistical analyses were carried out in accordance with the data distribution. The results showed that the patients and controls differed significantly. The majority of the patients were above 70 years of age, and they had much higher PSA values combined with significantly decreased haemoglobin, red blood cell counts, and testosterone levels. The most common complaint, according to the symptom analysis, was frequent urination. This was followed by difficulties urinating and, less commonly, back or bladder pain. According to lifestyle data, smoking was the least reported behaviour, while eating a normal diet was the most common, followed by exercise. These findings emphasise how crucial it is to use a multifaceted diagnostic strategy that incorporates biological, behavioural, and demographic factors in order to increase diagnostic precision and maximise treatment plans.
References
Black, A., Pinsky, P. F., Grubb, R. L., Falk, R. T., Hsing, A. W., Chu, L., Meyer, T., Veenstra, T. D., Xu, X., Yu, K., Ziegler, R. G., Brinton, L. A., Hoover, R. N., & Cook, M. B. (2014). Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer. Cancer Epidemiology, Biomarkers & Prevention, 23(11), 2374–2382.
Chu, F., Chen, L., Guan, Q., Chen, Z., Ji, Q., Ma, Y., ... & Zheng, Y. (2025). Global burden of prostate cancer: age-period-cohort analysis from 1990 to 2021 and projections until 2040. World Journal of Surgical Oncology, 23(1), 98.
Claps, M., Petrelli, F., Caffo, O., Amoroso, V., Roca, E., Mosca, A., ... & Berruti, A. (2018). Testosterone levels and prostate cancer prognosis: systematic review and meta-analysis. Clinical genitourinary cancer, 16(3), 165-175.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Lawrence Erlbaum Associates.
Dai, D., Han, S., Li, L., Guo, Y., Wei, Y., Jin, H., & Wang, X. (2018). Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis. American journal of translational research, 10(12), 3877.
Freedland, S. J., De Giorgi, U., Gleave, M., Rosbrook, B., Shen, Q., Sugg, J., ... & Shore, N. D. (2021). A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ open, 11(8), e046588.
Hakozaki, Y., Yamada, Y., Takeshima, Y., Taguchi, S., Kawai, T., Nakamura, M., ... & Kume, H. (2023). Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients. Scientific reports, 13(1), 2672.
Kania, E., Janica, M., Nesterowicz, M., Modzelewski, W., Cybulski, M., & Janica, J. (2025). Advances and Challenges in Prostate Cancer Diagnosis: A Comprehensive Review. Cancers, 17(13), 2137.
Karunasinghe, N., Minas, T. Z., Bao, B. Y., Lee, A., Wang, A., Zhu, S., ... & Ferguson, L. R. (2022). Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions. Scientific reports, 12(1), 55.
Kim, H., Lee, S., Byun, S. S., & Hong, S. K. (2021). Clinical outcomes and prognosis of metastatic prostate cancer patients≤ 60-year-old. World Journal of Urology, 39(12), 4319-4325.
Kim, K. S., Jo, J. K., Lee, J. A., Choi, B. Y., & Moon, H. S. (2019). Do lifestyle factors affect lower urinary tract symptoms? Results from the Korean community health survey. International Neurourology Journal, 23(2), 125.
Krashin, E., Piekiełko-Witkowska, A., Ellis, M., & Ashur-Fabian, O. (2019). Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Frontiers in endocrinology, 10, 59.
Liaqat, M., Kamal, S., & Fischer, F. (2023). Illustration of association between the change in prostate-specific antigen (PSA) values and time to tumor status after treatment for prostate cancer patients: a joint modelling approach. BMC urology, 23(1), 202.
Liu, X., & Jiang, H. (2025). The global, regional, and national prostate cancer burden and trends from 1990 to 2021, results from the global burden of disease study 2021. Frontiers in Public Health, 13, 1553747.
Machidori, A., Shiota, M., Kobayashi, S., Matsumoto, T., Monji, K., Kashiwagi, E., & Eto, M. (2021, June). Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors. In Urologic Oncology: Seminars and Original Investigations (Vol. 39, No. 6, pp. 365-e1). Elsevier.
Merriel, S. W., Pocock, L., Gilbert, E., Creavin, S., Walter, F. M., Spencer, A., & Hamilton, W. (2022). Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC medicine, 20(1), 54.
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022). Cancer treatment and survivorship statistics, 2022. CA: A Cancer Journal for Clinicians, 72(5), 409–436.
Noh, J. W., Yoo, K. B., Kim, K. B., Kim, J. H., & Kwon, Y. D. (2020). Association between lower urinary tract symptoms and cigarette smoking or alcohol drinking. Translational andrology and urology, 9(2), 312.
Pettersson, A., Robinson, D., Garmo, H., Holmberg, L., & Stattin, P. (2018). Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Annals of Oncology, 29(2), 377-385.
Tu, H., Gu, J., Meng, Q. H., Kim, J., Strom, S., Davis, J. W., ... & Wu, X. (2017). Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncology letters, 13(3), 1949-1957.
